Tìm theo
Propranolol
Các tên gọi khác (9 ) :
  • 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
  • 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
  • beta-Propranolol
  • Propanalol
  • Propanolol
  • Propranolol
  • Propranololo
  • Propranololum
  • β-Propranolol
Thuốc tim mạch
Thuốc Gốc
Small Molecule
CAS: 525-66-6
ATC: C07AA05
ĐG : Actavis Group , http://www.actavis.com
CTHH: C16H21NO2
PTK: 259.3434
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C16H21NO2
Phân tử khối
259.3434
Monoisotopic mass
259.157228921
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
InChI Key
InChIKey=AQHHHDLHHXJYJD-UHFFFAOYSA-N
IUPAC Name
[2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine
Traditional IUPAC Name
propranolol
SMILES
CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12
Độ tan chảy
96 °C
Độ hòa tan
61.7 mg/L (at 25 °C)
logP
3.48
logS
-3.5
pKa (strongest acidic)
14.09
pKa (Strongest Basic)
9.67
PSA
41.49 Å2
Refractivity
76.83 m3·mol-1
Polarizability
29.98 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
3
H Bond Donor Count
2
Physiological Charge
1
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
caco2 Permeability
-4.58
pKa
9.42
Dược Lực Học : Propranolol, the prototype of the beta-adrenergic receptor antagonists, is a competitive, nonselective beta-blocker similar to nadolol without intrinsic sympathomimetic activity. Propanolol is a racemic compound; the l-isomer is responsible for adrenergic blocking activity.
Cơ Chế Tác Dụng : A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem] Propranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
Dược Động Học :
▧ Absorption :
Propranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals.
▧ Volume of Distribution :
* 4 L
▧ Protein binding :
More than 90%
▧ Metabolism :
Hepatic
▧ Route of Elimination :
Propranolol is extensively metabolized with most metabolites appearing in the urine.
▧ Half Life :
4 hours
Độc Tính : Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD50=565 mg/kg (orally in mice).
Chỉ Định : For the prophylaxis of migraine.
Tương Tác Thuốc :
  • Acetohexamide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Aminophylline Antagonism of action and increased effect of theophylline
  • Bromazepam Co-administration with propranolol will cause a reduction in bromazepam clearance and increases half-life.
  • Chlorpromazine Increased effect of both drugs
  • Chlorpropamide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Cimetidine Cimetidine may increase the serum concentration of propranolol by decreasing its metabolism.
  • Citalopram The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, propranolol.
  • Clonidine Increased hypertension when clonidine stopped
  • Dihydroergotamine Ischemia with risk of gangrene
  • Diltiazem Increased risk of bradycardia
  • Disopyramide The beta-blocker, propranolol, may increase the toxicity of disopyramide.
  • Dronedarone Propranolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase propranolol exposure 1.3-fold. Lower dose of metoprolol.
  • Dyphylline Antagonism of action and increased effect of theophylline
  • Epinephrine Hypertension, then bradycardia
  • Ergonovine Ischemia with risk of gangrene
  • Ergotamine Ischemia with risk of gangrene
  • Escitalopram The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, propranolol.
  • Fenoterol Antagonism
  • Fluoxetine The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, propranolol.
  • Formoterol Antagonism
  • Gliclazide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Glipizide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Glisoxepide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Glyburide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Glycodiazine The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Haloperidol Increased effect of both drugs
  • Hydralazine Increased effect of both drugs
  • Ibuprofen Risk of inhibition of renal prostaglandins
  • Indacaterol Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
  • Indomethacin Risk of inhibition of renal prostaglandins
  • Insulin Glargine The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Isoprenaline Antagonism
  • Lidocaine The beta-blocker, propranolol, may increase the effect and toxicity of lidocaine.
  • Maprotiline Propranolol increases the serum levels of cisapride
  • Mesoridazine Increased risk of cardiotoxicity and arrhythmias
  • Methyldopa Possible hypertensive crisis
  • Methysergide Ischemia with risk of gangrene
  • Orciprenaline Antagonism
  • Oxtriphylline Antagonism of action and increased effect of theophylline
  • Paroxetine The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, propranolol.
  • Phenobarbital The barbiturate decreases the effect of the metabolized beta-blocker
  • Pipobroman Antagonism
  • Pirbuterol Antagonism
  • Piroxicam Risk of inhibition of renal prostaglandins
  • Prazosin Risk of hypotension at the beginning of therapy
  • Primidone The barbiturate decreases the effect of metabolized beta-blocker
  • Procaterol Antagonism
  • Propafenone Propafenone may increase the effect of the beta-blocker, propranolol.
  • Repaglinide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Rifampicin Rifampin may decrease the serum concentration of propranolol by increasing its metabolism.
  • Rizatriptan Propranolol increases the effect and toxicity of rizatriptan
  • Salbutamol Antagonism
  • Salmeterol Antagonism
  • Sertraline The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, propranolol.
  • Terazosin Increased risk of hypotension. Initiate concomitant therapy cautiously.
  • Terbinafine Terbinafine may reduce the metabolism and clearance of Propranolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Propranolol if Terbinafine is initiated, discontinued or dose changed.
  • Terbutaline Antagonism
  • Theophylline Antagonism of action and increased effect of theophylline
  • Thioridazine Increased risk of cardiotoxicity and arrhythmias
  • Tolazamide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Tolbutamide The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
  • Topotecan The p-glycoprotein inhibitor, Propranolol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
  • Verapamil Increased effect of both drugs
Liều Lượng & Cách Dùng : Capsule, extended release - Oral
Solution - Intravenous
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Angilol
  • Công ty :
    Sản phẩm biệt dược : Bedranol SR
  • Công ty :
    Sản phẩm biệt dược : Cardinol
  • Công ty :
    Sản phẩm biệt dược : Ciplar
  • Công ty :
    Sản phẩm biệt dược : Deralin
  • Công ty :
    Sản phẩm biệt dược : Dociton
  • Công ty :
    Sản phẩm biệt dược : Duranol
  • Công ty :
    Sản phẩm biệt dược : HEMANGEOL
  • Công ty :
    Sản phẩm biệt dược : Inderal
  • Công ty :
    Sản phẩm biệt dược : Inderal LA
  • Công ty :
    Sản phẩm biệt dược : Indobloc
  • Công ty :
    Sản phẩm biệt dược : INNOPRAN
  • Công ty :
    Sản phẩm biệt dược : Innopran XL
  • Công ty :
    Sản phẩm biệt dược : Prophylux
  • Công ty :
    Sản phẩm biệt dược : Sumial
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00571
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=4946
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505387
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07407
ChemSpider
http://www.chemspider.com/Chemical-Structure.4777.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25761
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/65726-251-10
PharmGKB
http://www.pharmgkb.org/drug/PA451145
Wikipedia
http://en.wikipedia.org/wiki/Propranolol
RxList
http://www.rxlist.com/cgi/generic/propran.htm
Drugs.com
http://www.drugs.com/propranolol.html
... loading
... loading